Aclipse Therapeutics is a clinical-stage biopharmaceutical company led by executives with experience taking drug candidates from research through regulatory development and commercial transactions. Its work centers on disease-modifying treatments for severe neuromuscular conditions, including M102 for ALS, using biological insights to identify patients most likely to respond.
Clene Nanomedicine, IncClene Nanomedicine is a clinical-stage biopharmaceutical company co-founded in 2013 and focused on developing treatments for neurodegenerative disease. Its patented electro-crystal-chemistry process produces clean-surfaced nanocrystals, including the investigational gold-based candidate CNM-Au8 for people living with ALS.NORTH EAST, MD
Axsome Therapeutics, IncFounded in January 2012 by physician Herriot Tabuteau, Axsome Therapeutics is a New York biopharmaceutical company focused on central nervous system conditions with limited treatment options. Its work centers on developing therapies intended to give patients and physicians new approaches where existing care falls short.NEW YORK, NY
Galimedix Therapeutics, IncGalimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing oral and topical small-molecule therapies for neurodegenerative diseases of the eye and brain. Its lead candidate, GAL-101, targets misfolded amyloid beta before toxic oligomers form and is being studied as an eye drop for geographic atrophy, an advanced form of dry age-related macular degeneration. The company’s approach also supports planned development in glaucoma and Alzheimer’s disease, with ophthalmology commercialization backed by Théa Open Innovation.KENSINGTON, MD